Telomir Pharmaceuticals Unveils Promising Inhibition Data for Telomir-1

Telomir Pharmaceuticals, Inc. has announced new findings that show its compound, Telomir-1, can inhibit enzymes crucial to tumor growth and other diseases. Conducted with Eurofins Discovery, the study highlights Telomir-1's potential in treating cancer, autoimmune diseases, and neurodegeneration.

Telomir-1 effectively inhibits three key enzymes: JMJD3, FBXL10, and FBXL11. These histone demethylases play roles in gene expression linked to cancer progression, immune function, and neuroinflammation. Historically hard to target, the inhibition of these enzymes by Telomir-1 offers potential breakthroughs in multiple therapeutic areas.

The compound's efficacy in reactivating tumor suppressor genes and modulating immune response underscores its therapeutic promise. These preclinical findings set the foundation for further studies and potential clinical applications.